1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hemophilia Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hemophilia Treatment Market, by Type
8.1.1. Hemophilia A
8.1.1.1. Market Revenue and Forecast
8.1.2. Hemophilia B
8.1.2.1. Market Revenue and Forecast
9.1. Hemophilia Treatment Market, by Drug Therapy
9.1.1. Recombinant Coagulation Factor Concentrates Therapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Plasma-derived Coagulation Factor Concentrates Therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Non-factor Replacement Therapy
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type
10.1.2. Market Revenue and Forecast, by Drug Therapy
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Type
10.1.3.2. Market Revenue and Forecast, by Drug Therapy
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Type
10.1.4.2. Market Revenue and Forecast, by Drug Therapy
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type
10.2.2. Market Revenue and Forecast, by Drug Therapy
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Type
10.2.3.2. Market Revenue and Forecast, by Drug Therapy
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Type
10.2.4.2. Market Revenue and Forecast, by Drug Therapy
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Type
10.2.5.2. Market Revenue and Forecast, by Drug Therapy
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Type
10.2.6.2. Market Revenue and Forecast, by Drug Therapy
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type
10.3.2. Market Revenue and Forecast, by Drug Therapy
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Type
10.3.3.2. Market Revenue and Forecast, by Drug Therapy
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Type
10.3.4.2. Market Revenue and Forecast, by Drug Therapy
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Type
10.3.5.2. Market Revenue and Forecast, by Drug Therapy
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Type
10.3.6.2. Market Revenue and Forecast, by Drug Therapy
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type
10.4.2. Market Revenue and Forecast, by Drug Therapy
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Type
10.4.3.2. Market Revenue and Forecast, by Drug Therapy
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Type
10.4.4.2. Market Revenue and Forecast, by Drug Therapy
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Type
10.4.5.2. Market Revenue and Forecast, by Drug Therapy
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Type
10.4.6.2. Market Revenue and Forecast, by Drug Therapy
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type
10.5.2. Market Revenue and Forecast, by Drug Therapy
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Type
10.5.3.2. Market Revenue and Forecast, by Drug Therapy
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Type
10.5.4.2. Market Revenue and Forecast, by Drug Therapy
11.1. Pfizer Inc. (U.S.)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Novo Nordisk A/S (Denmark)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. F. Hoffmann-La Roche Ltd (Switzerland)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer AG (Germany)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Shire (Ireland)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. CSL Behring (Australia)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Grifols, S.A. (Spain)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Biogen Inc. (U.S.)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sanofi S.A. (France)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BioMarin Pharmaceutical Inc. (U.S.)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
